Ultrasensitive circulating tumor DNA analysis enables precision medicine: experimental workflow considerations

References

• Thierry AR, El Messaoudi S, Gahan PB, et al. Origins, structures, and functions of circulating DNA in oncology. Cancer Metastasis Rev. 2016;35(3):347–376.
   PubMed Web of Science ®Google Scholar
• Crowley E, Di Nicolantonio F, Loupakis F, et al. Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol. 2013 Aug;10(8):472–484.
   PubMed Web of Science ®Google Scholar
• Tie J, Wang Y, Tomasetti C, et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med. 2016;8(346):346ra92.
   PubMed Web of Science ®Google Scholar
• Reinert T, Henriksen TV, Christensen E, et al. Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer. JAMA Oncol. 2019;5(8):1124–1131.
   PubMed Web of Science ®Google Scholar
• Wang Y, Li L, Cohen JD, et al. Prognostic Potential of Circulating Tumor DNA Measurement in Postoperative Surveillance of Nonmetastatic Colorectal Cancer. JAMA Oncol. 2019;5(8):1118–1123.
   Web of Science ®Google Scholar
• Wan JCM, Heider K, Gale D, et al. ctDNA monitoring using patient-specific sequencing and integration of variant reads. Sci Transl Med. 2020;12(548):eaaz8084.
   Web of Science ®Google Scholar
• Mok T, Wu YL, Lee JS, et al. Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy. Clin Cancer Res. 2015;21(14):3196–3203.
   PubMed Web of Science ®Google Scholar
• Zill OA, Banks KC, Fairclough SR, et al. The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients. Clin Cancer Res. 2018;24(15):3528–3538.
   PubMed Web of Science ®Google Scholar
• Cohen JD, Li L, Wang Y, et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science. 2018;359(6378):926–930.
   PubMed Web of Science ®Google Scholar
• Lennon AM, Buchanan AH, Kinde I, et al. Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention. Science. 2020;369(6499):eabb9601.
   PubMed Web of Science ®Google Scholar
• Chen X, Gole J, Gore A, et al. Non-invasive early detection of cancer four years before conventional diagnosis using a blood test. Nat Commun. 2020;11(1):3475.
   PubMed Web of Science ®Google Scholar
• Cavallone L, Aguilar-Mahecha A, Lafleur J, et al. Prognostic and predictive value of circulating tumor DNA during neoadjuvant chemotherapy for triple negative breast cancer. Sci Rep. 2020;10(1):14704.
   PubMed Web of Science ®Google Scholar
• Pietrasz D, Pecuchet N, Garlan F, et al. Plasma Circulating Tumor DNA in Pancreatic Cancer Patients Is a Prognostic Marker. Clin Cancer Res. 2017;23(1):116–123.
   PubMed Web of Science ®Google Scholar
• Heitzer E, Ulz P, Geigl JB. Circulating tumor DNA as a liquid biopsy for cancer. Clin Chem. 2015;611:112–123.
   PubMed Web of Science ®Google Scholar
• Shen SY, Singhania R, Fehringer G, et al. Sensitive tumour detection and classification using plasma cell-free DNA methylomes. Nature. 2018;563(7732):579–583.
   PubMed Web of Science ®Google Scholar
• Cristiano S, Leal A, Phallen J, et al. Genome-wide cell-free DNA fragmentation in patients with cancer. Nature. 2019;570(7761):385–389.
   PubMed Web of Science ®Google Scholar
• Bronkhorst AJ, Ungerer V, Holdenrieder S. The emerging role of cell-free DNA as a molecular marker for cancer management. Biomol Detect Quantif. 2019;17:100087.
   PubMedGoogle Scholar
• Andersson D, Kubista M, Stahlberg A. Liquid biopsy analysis in cancer diagnostics. Mol Aspects Med. 2020;72:100839.
   PubMed Web of Science ®Google Scholar
• Lo YM, Chan KC, Sun H, et al. Maternal plasma DNA sequencing reveals the genome-wide genetic and mutational profile of the fetus. Sci Transl Med. 2010;2(61):61ra91.
   PubMed Web of Science ®Google Scholar
• Zheng YW, Chan KC, Sun H, et al. Nonhematopoietically derived DNA is shorter than hematopoietically derived DNA in plasma: a transplantation model. Clin Chem. 2012;58(3):549–558.
   PubMed Web of Science ®Google Scholar
• Wan JCM, Massie C, Garcia-Corbacho J, et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer. 2017;17(4):223–238.
   PubMed Web of Science ®Google Scholar
• Jahr S, Hentze H, Englisch S, et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 2001;61(4):1659–1665.
   PubMed Web of Science ®Google Scholar
• Ivanov M, Baranova A, Butler T, et al. Non-random fragmentation patterns in circulating cell-free DNA reflect epigenetic regulation. BMC Genomics. 2015;16(Suppl 13):S1.
   Web of Science ®Google Scholar
• Swinson DEB, Jones JL, Richardson D, et al. Tumour necrosis is an independent prognostic marker in non-small cell lung cancer: correlation with biological variables. Lung Cancer. 2002 Sep;37(3):235–240.
   PubMed Web of Science ®Google Scholar
• Langner C, Hutterer G, Chromecki T, et al. Tumor necrosis as prognostic indicator in transitional cell carcinoma of the upper urinary tract. J Urol. 2006;176(3):910–913.
   PubMed Web of Science ®Google Scholar
• Hiraoka N, Ino Y, Sekine S, et al. Tumour necrosis is a postoperative prognostic marker for pancreatic cancer patients with a high interobserver reproducibility in histological evaluation. Br J Cancer. 2010;103(7):1057–1065.
   PubMed Web of Science ®Google Scholar
• Bronkhorst AJ, Wentzel JF, Aucamp J, et al. Characterization of the cell-free DNA released by cultured cancer cells. Biochim Biophys Acta. 2016;1863(1):157–165.
   PubMed Web of Science ®Google Scholar
• Bronkhorst AJ, Wentzel JF, Ungerer V, et al. Sequence analysis of cell-free DNA derived from cultured human bone osteosarcoma (143B) cells. Tumour Biol. 2018;40(9):1010428318801190.
   Google Scholar
• Stewart CM, Tsui DWY. Circulating cell-free DNA for non-invasive cancer management. Cancer Genet. 2018;228-229:169–179.
   PubMed Web of Science ®Google Scholar
• Tamkovich SN, Cherepanova AV, Kolesnikova EV, et al. Circulating DNA and DNase activity in human blood. Ann N Y Acad Sci. 2006;1075:191–196.
   PubMed Web of Science ®Google Scholar
• Cherepanova AV, Tamkovich SN, Bryzgunova OE, et al. Deoxyribonuclease activity and circulating DNA concentration in blood plasma of patients with prostate tumors. Ann Ny Acad Sci. 2008;1137:218–221.
   PubMed Web of Science ®Google Scholar
• Yu SC, Lee SW, Jiang P, et al. High-resolution profiling of fetal DNA clearance from maternal plasma by massively parallel sequencing. Clin Chem. 2013;59(8):1228–1237.
   PubMed Web of Science ®Google Scholar
• Reckamp KL, Melnikova VO, Karlovich C, et al. A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma. J Thorac Oncol. 2016;11(10):1690–1700.
   PubMed Web of Science ®Google Scholar
• Chused TM, Steinberg AD, Talal N. The clearance and localization of nucleic acids by New Zealand and normal mice. Clin Exp Immunol. 1972 Dec;12(4):465–476.
   PubMed Web of Science ®Google Scholar
• Minchin RF, Carpenter D, Orr RJ. Polyinosinic acid and polycationic liposomes attenuate the hepatic clearance of circulating plasmid DNA. J Pharmacol Exp Ther. 2001;296(3):1006–1012.
   PubMed Web of Science ®Google Scholar
• Lau TW, Leung TN, Chan LY, et al. Fetal DNA clearance from maternal plasma is impaired in preeclampsia. Clin Chem. 2002 Dec;48(12):2141–2146.
   PubMed Web of Science ®Google Scholar
• Nelson M, Eagle C, Langshaw M, et al. Genotyping fetal DNA by non-invasive means: extraction from maternal plasma. Vox Sang. 2001 Feb;80(2):112–116.
   PubMed Web of Science ®Google Scholar
• Larzabal L, El-Nikhely N, Redrado M, et al. Differential effects of drugs targeting cancer stem cell (CSC) and non-CSC populations on lung primary tumors and metastasis. PLoS One. 2013;8(11):e79798.
   PubMed Web of Science ®Google Scholar
• Uchida J, Imamura F, Kukita Y, et al. Dynamics of circulating tumor DNA represented by the activating and resistant mutations in epidermal growth factor receptor tyrosine kinase inhibitor treatment. Cancer Sci. 2016;107(3):353–358.
   PubMed Web of Science ®Google Scholar
• Hur W, Yoon SK. Molecular Pathogenesis of Radiation-Induced Cell Toxicity in Stem Cells. Int J Mol Sci. 2017;18(12):2749.
   Web of Science ®Google Scholar
• Andersson D, Fagman H, Dalin MG, et al. Circulating cell-free tumor DNA analysis in pediatric cancers. Mol Aspects Med. 2020;72:100819.
   PubMed Web of Science ®Google Scholar
• Mead R, Duku M, Bhandari P, et al. Circulating tumour markers can define patients with normal colons, benign polyps, and cancers. Br J Cancer. 2011;105(2):239–245.
   PubMed Web of Science ®Google Scholar
• Mouliere F, El Messaoudi S, Pang DL, et al. Multi-marker analysis of circulating cell-free DNA toward personalized medicine for colorectal cancer. Mol Oncol. 2014;8(5):927–941.
   PubMed Web of Science ®Google Scholar
• Haller N, Helmig S, Taenny P, et al. Circulating, cell-free DNA as a marker for exercise load in intermittent sports. PLoS One. 2018;13(1):e0191915.
   PubMed Web of Science ®Google Scholar
• Piovesan A, Pelleri MC, Antonaros F, et al. On the length, weight and GC content of the human genome. BMC Res Notes. 2019;12(1):106.
   PubMedGoogle Scholar
• Moss J, Magenheim J, Neiman D, et al. Comprehensive human cell-type methylation atlas reveals origins of circulating cell-free DNA in health and disease. Nat Commun. 2018;9(1):5068.
   PubMed Web of Science ®Google Scholar
• Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6(224):224ra24.
   PubMed Web of Science ®Google Scholar
• Schwarzenbach H, Hoon DS, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer. 2011;11(6):426–437.
   PubMed Web of Science ®Google Scholar
• Newman AM, Bratman SV, To J, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med. 2014;20(5):552–558.
   Web of Science ®Google Scholar
• Abbosh C, Birkbak NJ, Wilson GA, et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2017;545(7655):446–451.
   PubMed Web of Science ®Google Scholar
• Diehl F, Li M, Dressman D, et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci U S A. 2005;102(45):16368–16373.
   PubMed Web of Science ®Google Scholar
• Xu RH, Wei W, Krawczyk M, et al. Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma. Nat Mater. 2017;16(11):1155.
   PubMed Web of Science ®Google Scholar
• Garcia-Saenz JA, Ayllon P, Laig M, et al. Tumor burden monitoring using cell-free tumor DNA could be limited by tumor heterogeneity in advanced breast cancer and should be evaluated together with radiographic imaging. BMC Cancer. 2017;17(1):210.
   PubMedGoogle Scholar
• Nygaard AD, Holdgaard PC, Spindler KL, et al. The correlation between cell-free DNA and tumour burden was estimated by PET/CT in patients with advanced NSCLC. Br J Cancer. 2014;110(2):363–368.
   PubMed Web of Science ®Google Scholar
• Atamaniuk J, Vidotto C, Tschan H, et al. Increased concentrations of cell-free plasma DNA after exhaustive exercise. Clin Chem. 2004;50(9):1668–1670.
   PubMed Web of Science ®Google Scholar
• Haghiac M, Vora NL, Basu S, et al. Increased death of adipose cells, a path to release cell-free DNA into systemic circulation of obese women. Obesity (Silver Spring). 2012;20(11):2213–2219.
   PubMed Web of Science ®Google Scholar
• Paunel-Gorgulu A, Wacker M, El Aita M, et al. cfDNA correlates with endothelial damage after cardiac surgery with prolonged cardiopulmonary bypass and amplifies NETosis in an intracellular TLR9-independent manner. Sci Rep. 2017;7(1):17421.
   PubMedGoogle Scholar
• Johansson G, Andersson D, Filges S, et al. Considerations and quality controls when analyzing cell-free tumor DNA. Biomol Detect Quantif. 2019;17:100078.
   PubMedGoogle Scholar
• Keller L, Belloum Y, Wikman H, et al. Clinical relevance of blood-based ctDNA analysis: mutation detection and beyond. Br J Cancer. 2021;124(2):345–358.
   Google Scholar
• Ponti G, Maccaferri M, Manfredini M, et al. The value of fluorimetry (Qubit) and spectrophotometry (NanoDrop) in the quantification of cell-free DNA (cfDNA) in malignant melanoma and prostate cancer patients. Clin Chim Acta. 2018;479:14–19.
   PubMed Web of Science ®Google Scholar
• Kumar M, Choudhury Y, Ghosh SK, et al. Application and optimization of minimally invasive cell-free DNA techniques in oncogenomics. Tumour Biol. 2018;40(2):1010428318760342.
   Google Scholar
• Alidousty C, Brandes D, Heydt C, et al. Comparison of Blood Collection Tubes from Three Different Manufacturers for the Collection of Cell-Free DNA for Liquid Biopsy Mutation Testing. J Mol Diagn. 2017;19(5):801–804.
   PubMed Web of Science ®Google Scholar
• Barrett AN, Thadani HA, Laureano-Asibal C, et al. Stability of cell-free DNA from maternal plasma isolated following a single centrifugation step. Prenat Diagn. 2014;34(13):1283–1288.
   PubMed Web of Science ®Google Scholar
• Bartak BK, Kalmar A, Galamb O, et al. Blood Collection and Cell-Free DNA Isolation Methods Influence the Sensitivity of Liquid Biopsy Analysis for Colorectal Cancer Detection. Pathol Oncol Res. 2019;25(3):915–923.
   PubMed Web of Science ®Google Scholar
• Board RE, Williams VS, Knight L, et al. Isolation and extraction of circulating tumor DNA from patients with small cell lung cancer. Ann N Y Acad Sci. 2008;1137:98–107.
   PubMed Web of Science ®Google Scholar
• Breitbach S, Tug S, Helmig S, et al. Direct quantification of cell-free, circulating DNA from unpurified plasma. PLoS One. 2014;9(3):e87838.
   PubMed Web of Science ®Google Scholar
• Denis MG, Knol AC, Theoleyre S, et al. Efficient Detection of BRAF Mutation in Plasma of Patients after Long-term Storage of Blood in Cell-Free DNA Blood Collection Tubes. Clin Chem. 2015;61(6):886–888.
   PubMed Web of Science ®Google Scholar
• Fleischhacker M, Schmidt B, Weickmann S, et al. Methods for isolation of cell-free plasma DNA strongly affect DNA yield. Clin Chim Acta. 2011;412(23–24):2085–2088.
   PubMed Web of Science ®Google Scholar
• Henao Diaz E, Yachnin J, Gronberg H, et al. The In Vitro Stability of Circulating Tumour DNA. PLoS One. 2016;11(12):e0168153.
   PubMed Web of Science ®Google Scholar
• Hidestrand M, Stokowski R, Song K, et al. Influence of temperature during transportation on cell-free DNA analysis. Fetal Diagn Ther. 2012;31(2):122–128.
   PubMed Web of Science ®Google Scholar
• Kim K, Shin DG, Park MK, et al. Circulating cell-free DNA as a promising biomarker in patients with gastric cancer: diagnostic validity and significant reduction of cfDNA after surgical resection. Ann Surg Treat Res. 2014;86(3):136–142.
   PubMed Web of Science ®Google Scholar
• Kloten V, Ruchel N, Bruchle NO, et al. Liquid biopsy in colon cancer: comparison of different circulating DNA extraction systems following absolute quantification of KRAS mutations using Intplex allele-specific PCR. Oncotarget. 2017;8(49):86253–86263.
   PubMedGoogle Scholar
• Mazurek AM, Fiszer-Kierzkowska A, Rutkowski T, et al. Optimization of circulating cell-free DNA recovery for KRAS mutation and HPV detection in plasma. Cancer Biomark. 2013;13(5):385–394.
   PubMed Web of Science ®Google Scholar
• Medina Diaz I, Nocon A, Mehnert DH, et al. Performance of Streck cfDNA Blood Collection Tubes for Liquid Biopsy Testing. PLoS One. 2016;11(11):e0166354.
   PubMed Web of Science ®Google Scholar
• Mehrotra M, Singh RR, Chen W, et al. Study of Preanalytic and Analytic Variables for Clinical Next-Generation Sequencing of Circulating Cell-Free Nucleic Acid. J Mol Diagn. 2017;19(4):514–524.
   PubMed Web of Science ®Google Scholar
• Page K, Guttery DS, Zahra N, et al. Influence of plasma processing on recovery and analysis of circulating nucleic acids. PLoS One. 2013;8(10):e77963.
   PubMed Web of Science ®Google Scholar
• Perez-Barrios C, Nieto-Alcolado I, Torrente M, et al. Comparison of methods for circulating cell-free DNA isolation using blood from cancer patients: impact on biomarker testing. Transl Lung Cancer Res. 2016;5(6):665–672.
   PubMed Web of Science ®Google Scholar
• Rothwell DG, Smith N, Morris D, et al. Genetic profiling of tumours using both circulating free DNA and circulating tumour cells isolated from the same preserved whole blood sample. Mol Oncol. 2016;10(4):566–574.
   PubMed Web of Science ®Google Scholar
• Schmidt B, Reinicke D, Reindl I, et al. Liquid biopsy - Performance of the PAXgene(R) Blood ccfDNA Tubes for the isolation and characterization of cell-free plasma DNA from tumor patients. Clin Chim Acta. 2017;469:94–98.
   PubMed Web of Science ®Google Scholar
• Sherwood JL, Corcoran C, Brown H, et al. Optimised Pre-Analytical Methods Improve KRAS Mutation Detection in Circulating Tumour DNA (ctDNA) from Patients with Non-Small Cell Lung Cancer (NSCLC). PLoS One. 2016;11(2):e0150197.
   PubMed Web of Science ®Google Scholar
• Swinkels DW, Wiegerinck E, Steegers EA, et al. Effects of blood-processing protocols on cell-free DNA quantification in plasma. Clin Chem. 2003;49(3):525–526.
   PubMed Web of Science ®Google Scholar
• Toro PV, Erlanger B, Beaver JA, et al. Comparison of cell stabilizing blood collection tubes for circulating plasma tumor DNA. Clin Biochem. 2015;48(15):993–998.
   PubMed Web of Science ®Google Scholar
• van Dessel LF, Beije N, Helmijr JC, et al. Application of circulating tumor DNA in prospective clinical oncology trials - standardization of preanalytical conditions. Mol Oncol. 2017;11(3):295–304.
   PubMed Web of Science ®Google Scholar
• van Ginkel JH, van den Broek DA, van Kuik J, et al. Preanalytical blood sample workup for cell-free DNA analysis using Droplet Digital PCR for future molecular cancer diagnostics. Cancer Med. 2017;6(10):2297–2307.
   PubMed Web of Science ®Google Scholar
• Warton K, Yuwono NL, Cowley MJ, et al. Evaluation of Streck BCT and PAXgene Stabilised Blood Collection Tubes for Cell-Free Circulating DNA Studies in Plasma. Mol Diagn Ther. 2017;21(5):563–570.
   PubMed Web of Science ®Google Scholar
• Wolf A, Beller K, Groemminger S, et al. Purification of Circulating Cell-Free DNA from Plasma and Urine Using the Automated Large-Volume Extraction on the QIAsymphony(R) SP Instrument. Adv Exp Med Biol. 2016;924:179–185.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Li Y, Chen P, et al. Performance comparison of blood collection tubes as liquid biopsy storage system for minimizing cfDNA contamination from genomic DNA. J Clin Lab Anal. 2019;33(2):e22670.
   PubMed Web of Science ®Google Scholar
• Parpart-Li S, Bartlett B, Popoli M, et al. The Effect of Preservative and Temperature on the Analysis of Circulating Tumor DNA. Clin Cancer Res. 2017;23(10):2471–2477.
   PubMed Web of Science ®Google Scholar
• Trigg RM, Martinson LJ, Parpart-Li S, et al. Factors that influence quality and yield of circulating-free DNA: a systematic review of the methodology literature. Heliyon. 2018;4(7):e00699.
   PubMed Web of Science ®Google Scholar
• Gerber T, Taschner-Mandl S, Saloberger-Sindhoringer L, et al. Assessment of Pre-Analytical Sample Handling Conditions for Comprehensive Liquid Biopsy Analysis. J Mol Diagn. 2020;22(8):1070–1086.
   PubMed Web of Science ®Google Scholar
• Barra GB, Santa Rita TH, de Almeida Vasques J, et al. EDTA-mediated inhibition of DNases protects circulating cell-free DNA from ex vivo degradation in blood samples. Clin Biochem. 2015;48(15):976–981.
   PubMed Web of Science ®Google Scholar
• Risberg B, Tsui DWY, Biggs H, et al. Effects of Collection and Processing Procedures on Plasma Circulating Cell-Free DNA from Cancer Patients. J Mol Diagn. 2018;20(6):883–892.
   PubMed Web of Science ®Google Scholar
• Lam NY, Rainer TH, Chiu RW, et al. EDTA is a better anticoagulant than heparin or citrate for delayed blood processing for plasma DNA analysis. Clin Chem. 2004;50(1):256–257.
   PubMed Web of Science ®Google Scholar
• Helgadottir H, Olafsson I, Andersen K, et al. Stability of thromboxane in blood samples. Vasc Health Risk Manag. 2019;15:143–147.
   PubMed Web of Science ®Google Scholar
• Keowmaneechai E, McClements DJ. Influence of EDTA and citrate on physicochemical properties of whey protein-stabilized oil-in-water emulsions containing CaCl2. J Agric Food Chem. 2002;50(24):7145–7153.
   PubMed Web of Science ®Google Scholar
• Beutler E, Gelbart T, Kuhl W. Interference of heparin with the polymerase chain reaction. Biotechniques. 1990;9(2):166.
   PubMed Web of Science ®Google Scholar
• Ungerer V, Bronkhorst AJ, Holdenrieder S. Preanalytical variables that affect the outcome of cell-free DNA measurements. Crit Rev Clin Lab Sci. 2020;57(7):484–507.
   PubMed Web of Science ®Google Scholar
• Nikolaev S, Lemmens L, Koessler T, et al. Circulating tumoral DNA: preanalytical validation and quality control in a diagnostic laboratory. Anal Biochem. 2018;542:34–39.
   PubMed Web of Science ®Google Scholar
• Sozzi G, Roz L, Conte D, et al. Effects of prolonged storage of whole plasma or isolated plasma DNA on the results of circulating DNA quantification assays. J Natl Cancer Inst. 2005;97(24):1848–1850.
   PubMedGoogle Scholar
• Sato A, Nakashima C, Abe T, et al. Investigation of appropriate pre-analytical procedure for circulating free DNA from liquid biopsy. Oncotarget. 2018;9(61):31904–31914.
   PubMedGoogle Scholar
• Norton SE, Lechner JM, Williams T, et al. A stabilizing reagent prevents cell-free DNA contamination by cellular DNA in plasma during blood sample storage and shipping as determined by digital PCR. Clin Biochem. 2013;46(15):1561–1565.
   PubMed Web of Science ®Google Scholar
• Ward Gahlawat A, Lenhardt J, Witte T, et al. Evaluation of Storage Tubes for Combined Analysis of Circulating Nucleic Acids in Liquid Biopsies. Int J Mol Sci. 2019;20(3):704.
   PubMed Web of Science ®Google Scholar
• Wong D, Moturi S, Angkachatchai V, et al. Optimizing blood collection, transport and storage conditions for cell free DNA increases access to prenatal testing. Clin Biochem. 2013;46(12):1099–1104.
   PubMed Web of Science ®Google Scholar
• Norton SE, Luna KK, Lechner JM, et al. A new blood collection device minimizes cellular DNA release during sample storage and shipping when compared to a standard device. J Clin Lab Anal. 2013;27(4):305–311.
   PubMed Web of Science ®Google Scholar
• Sorber L, Zwaenepoel K, Jacobs J, et al. Circulating Cell-Free DNA and RNA Analysis as Liquid Biopsy: optimal Centrifugation Protocol. Cancers (Basel). 2019;11(4):458.
   PubMed Web of Science ®Google Scholar
• Raymond CK, Hernandez J, Karr R, et al. Collection of cell-free DNA for genomic analysis of solid tumors in a clinical laboratory setting. PLoS One. 2017;12(4):e0176241.
   PubMed Web of Science ®Google Scholar
• Chan KC, Yeung SW, Lui WB, et al. Effects of preanalytical factors on the molecular size of cell-free DNA in blood. Clin Chem. 2005;51(4):781–784.
   PubMed Web of Science ®Google Scholar
• Diefenbach RJ, Lee JH, Kefford RF, et al. Evaluation of commercial kits for purification of circulating free DNA. Cancer Genet. 2018;228-229:21–27.
   PubMed Web of Science ®Google Scholar
• Devonshire AS, Whale AS, Gutteridge A, et al. Towards standardisation of cell-free DNA measurement in plasma: controls for extraction efficiency, fragment size bias and quantification. Anal Bioanal Chem. 2014;406(26):6499–6512.
   PubMed Web of Science ®Google Scholar
• Markus H, Contente-Cuomo T, Farooq M, et al. Evaluation of pre-analytical factors affecting plasma DNA analysis. Sci Rep. 2018;8(1):7375.
   PubMedGoogle Scholar
• Sorber L, Zwaenepoel K, Deschoolmeester V, et al. A Comparison of Cell-Free DNA Isolation Kits: isolation and Quantification of Cell-Free DNA in Plasma. J Mol Diagn. 2017;19(1):162–168.
   PubMed Web of Science ®Google Scholar
• Warton K, Graham LJ, Yuwono N, et al. Comparison of 4 commercial kits for the extraction of circulating DNA from plasma. Cancer Genet. 2018;228-229:143–150.
   PubMed Web of Science ®Google Scholar
• Gyanchandani R, Kvam E, Heller R, et al. Whole genome amplification of cell-free DNA enables detection of circulating tumor DNA mutations from fingerstick capillary blood. Sci Rep. 2018;8(1):17313.
   PubMedGoogle Scholar
• Mauger F, Dulary C, Daviaud C, et al. Comprehensive evaluation of methods to isolate, quantify, and characterize circulating cell-free DNA from small volumes of plasma. Anal Bioanal Chem. 2015;407(22):6873–6878.
   PubMed Web of Science ®Google Scholar
• Rykova EY, Laktionov PP, Skvortsova TE, et al. Extracellular DNA in breast cancer: cell-surface-bound, tumor-derived extracellular DNA in blood of patients with breast cancer and nonmalignant tumors. Ann N Y Acad Sci. 2004;1022:217–220.
   PubMed Web of Science ®Google Scholar
• Skvortsova TE, Rykova EY, Tamkovich SN, et al. Cell-free and cell-bound circulating DNA in breast tumours: DNA quantification and analysis of tumour-related gene methylation. Br J Cancer. 2006;94(10):1492–1495.
   PubMed Web of Science ®Google Scholar
• Ordonez E, Rueda L, Canadas MP, et al. Evaluation of sample stability and automated DNA extraction for fetal sex determination using cell-free fetal DNA in maternal plasma. Biomed Res Int. 2013;2013:195363.
   PubMed Web of Science ®Google Scholar
• Stroun M, Anker P, Maurice P, et al. Neoplastic characteristics of the DNA found in the plasma of cancer patients. Oncology. 1989;46(5):318–322.
   PubMed Web of Science ®Google Scholar
• Mandel P, Metais P. Les acides du plasma sanguin chez l'homme. C R Seances Soc Biol Fil. 1948 Feb;142(3–4):241–243.
   PubMedGoogle Scholar
• Jaiswal S, Fontanillas P, Flannick J, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014 Dec 25;371(26):2488–2498.
   PubMed Web of Science ®Google Scholar
• Xie M, Lu C, Wang J, et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med. 2014;20(12):1472–1478.
   PubMed Web of Science ®Google Scholar
• Genovese G, Kahler AK, Handsaker RE, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014;371(26):2477–2487.
   PubMed Web of Science ®Google Scholar
• Salk JJ, Loubet-Senear K, Maritschnegg E, et al. Ultra-Sensitive TP53 Sequencing for Cancer Detection Reveals Progressive Clonal Selection in Normal Tissue over a Century of Human Lifespan. Cell Rep. 2019;28(1):132–144e3.
   PubMed Web of Science ®Google Scholar
• Yizhak K, Aguet F, Kim J, et al. RNA sequence analysis reveals macroscopic somatic clonal expansion across normal tissues. Science. 2019;364(6444):eaaw0726.
   PubMed Web of Science ®Google Scholar
• Alexandrov LB, Jones PH, Wedge DC, et al. Clock-like mutational processes in human somatic cells. Nat Genet. 2015;47(12):1402–1407.
   PubMed Web of Science ®Google Scholar
• Elazezy M, Joosse SA. Techniques of using circulating tumor DNA as a liquid biopsy component in cancer management. Comput Struct Biotechnol J. 2018;16:370–378.
   PubMed Web of Science ®Google Scholar
• Fox EJ, Reid-Bayliss KS, Emond MJ, et al. Accuracy of Next Generation Sequencing Platforms. Next Gener Seq Appl. 2014;1:1000106.
   Google Scholar
• Vogelstein B, Kinzler KW. Digital PCR. Proc Natl Acad Sci U S A. 1999;96(16):9236–9241.
   PubMed Web of Science ®Google Scholar
• Hindson BJ, Ness KD, Masquelier DA, et al. High-throughput droplet digital PCR system for absolute quantitation of DNA copy number. Anal Chem. 2011;83(22):8604–8610.
   PubMed Web of Science ®Google Scholar
• Li J, Wang L, Mamon H, et al. Replacing PCR with COLD-PCR enriches variant DNA sequences and redefines the sensitivity of genetic testing. Nat Med. 2008;14(5):579–584.
   PubMed Web of Science ®Google Scholar
• Belloum Y, Janning M, Mohme M, et al. Discovery of Targetable Genetic Alterations in NSCLC Patients with Different Metastatic Patterns Using a MassARRAY-Based Circulating Tumor DNA Assay. Cells. 2020;9(11):2337.
   PubMed Web of Science ®Google Scholar
• Huang CC, Du M, Wang L. Bioinformatics Analysis for Circulating Cell-Free DNA in Cancer. Cancers (Basel). 2019;11(6):805.
   Web of Science ®Google Scholar
• Filges S, Yamada E, Stahlberg A, et al. Impact of Polymerase Fidelity on Background Error Rates in Next-Generation Sequencing with Unique Molecular Identifiers/Barcodes. Sci Rep. 2019;9(1):3503.
   PubMedGoogle Scholar
• Johansson G, Kaltak M, Rimniceanu C, et al. Ultrasensitive DNA Immune Repertoire Sequencing Using Unique Molecular Identifiers. Clin Chem. 2020;66(9):1228–1237.
   PubMed Web of Science ®Google Scholar
• Kinde I, Wu J, Papadopoulos N, et al. Detection and quantification of rare mutations with massively parallel sequencing. Proc Natl Acad Sci U S A. 2011;108(23):9530–9535.
   PubMed Web of Science ®Google Scholar
• Jabara CB, Jones CD, Roach J, et al. Accurate sampling and deep sequencing of the HIV-1 protease gene using a Primer ID. Proc Natl Acad Sci U S A. 2011;108(50):20166–20171.
   PubMed Web of Science ®Google Scholar
• Mouliere F, Chandrananda D, Piskorz AM, et al. Enhanced detection of circulating tumor DNA by fragment size analysis. Sci Transl Med. 2018;10(466):eaat4921.
   PubMed Web of Science ®Google Scholar
• Scimia M, Du J, Pepe F, et al. Evaluation of a novel liquid biopsy-based ColoScape assay for mutational analysis of colorectal neoplasia and triage of FIT+ patients: a pilot study. J Clin Pathol. 2018;71(12):1123–1126.
   PubMed Web of Science ®Google Scholar
• Gan Q, Cui Z, Tang S, et al. A novel XNA-based NGS panel for cancer diagnostics. J Clin Oncol. 2020;38(15_suppl):e16142.
   Google Scholar
• Chan HT, Nagayama S, Chin YM, et al. Clinical significance of clonal hematopoiesis in the interpretation of blood liquid biopsy. Mol Oncol. 2020;14(8):1719–1730.
   PubMed Web of Science ®Google Scholar
• Hu Y, Ulrich BC, Supplee J, et al. False-Positive Plasma Genotyping Due to Clonal Hematopoiesis. Clin Cancer Res. 2018;24(18):4437–4443.
   PubMed Web of Science ®Google Scholar
• Barbany G, Arthur C, Lieden A, et al. Cell-free tumour DNA testing for early detection of cancer - a potential future tool. J Intern Med. 2019;286(2):118–136.
   PubMed Web of Science ®Google Scholar
• Fiala C, Diamandis EP. Utility of circulating tumor DNA in cancer diagnostics with emphasis on early detection. BMC Med. 2018;16(1):166.
   PubMedGoogle Scholar
• Bronkhorst AJ, Ungerer V, Holdenrieder S. Early detection of cancer using circulating tumor DNA: biological, physiological and analytical considerations. Crit Rev Clin Lab Sci. 2019:1–17.
   PubMed Web of Science ®Google Scholar
• Siravegna G, Mussolin B, Venesio T, et al. How liquid biopsies can change clinical practice in oncology. Ann Oncol. 2019;30(10):1580–1590.
   PubMed Web of Science ®Google Scholar
• Caramori G, Ruggeri P, Mumby S, et al. Molecular links between COPD and lung cancer: new targets for drug discovery? Expert Opin Ther Targets. 2019;23(6):539–553.
   PubMed Web of Science ®Google Scholar
• Weaver JMJ, Ross-Innes CS, Shannon N, et al. Ordering of mutations in preinvasive disease stages of esophageal carcinogenesis. Nat Genet. 2014;46(8):837–843.
   PubMed Web of Science ®Google Scholar
• Axelrad JE, Lichtiger S, Yajnik V. Inflammatory bowel disease and cancer: the role of inflammation, immunosuppression, and cancer treatment. World J Gastroenterol. 2016;22(20):4794–4801.
   PubMed Web of Science ®Google Scholar
• De Rubis G, Rajeev Krishnan S, Bebawy M. Liquid Biopsies in Cancer Diagnosis, Monitoring, and Prognosis. Trends Pharmacol Sci. 2019;40(3):172–186.
   PubMed Web of Science ®Google Scholar
• Xia S, Ye J, Chen Y, et al. Parallel serial assessment of somatic mutation and methylation profile from circulating tumor DNA predicts treatment response and impending disease progression in osimertinib-treated lung adenocarcinoma patients. Transl Lung Cancer Res. 2019;8(6):1016–1028.
   PubMed Web of Science ®Google Scholar
• Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366(10):883–892.
   PubMed Web of Science ®Google Scholar
• Bedard PL, Hansen AR, Ratain MJ, et al. Tumour heterogeneity in the clinic. Nature. 2013;501(7467):355–364.
   PubMed Web of Science ®Google Scholar
• Baslan T, Kendall J, Ward B, et al. Optimizing sparse sequencing of single cells for highly multiplex copy number profiling. Genome Res. 2015;25(5):714–724.
   PubMed Web of Science ®Google Scholar
• Berry JL, Xu L, Murphree AL, et al. Potential of Aqueous Humor as a Surrogate Tumor Biopsy for Retinoblastoma. JAMA Ophthalmol. 2017;135(11):1221–1230.
   PubMed Web of Science ®Google Scholar
• Pantel K, Alix-Panabieres C. Liquid biopsy and minimal residual disease - latest advances and implications for cure. Nat Rev Clin Oncol. 2019;16(7):409–424.
   PubMed Web of Science ®Google Scholar
• Lee JH, Long GV, Menzies AM, et al. Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti-Programmed Cell Death 1 Antibodies. JAMA Oncol. 2018;4(5):717–721.
   PubMed Web of Science ®Google Scholar
• Murtaza M, Dawson SJ, Tsui DW, et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature. 2013;497(7447):108–112.
   PubMed Web of Science ®Google Scholar
• Adalsteinsson VA, Ha G, Freeman SS, et al. Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. Nat Commun. 2017;8(1):1324.
   PubMed Web of Science ®Google Scholar
• Chicard M, Colmet-Daage L, Clement N, et al. Whole-Exome Sequencing of Cell-Free DNA Reveals Temporo-spatial Heterogeneity and Identifies Treatment-Resistant Clones in Neuroblastoma. Clin Cancer Res. 2018;24(4):939–949.
   PubMed Web of Science ®Google Scholar
• Seoane J, De Mattos-Arruda L, Le Rhun E, et al. Cerebrospinal fluid cell-free tumour DNA as a liquid biopsy for primary brain tumours and central nervous system metastases. Ann Oncol. 2019;30(2):211–218.
   PubMed Web of Science ®Google Scholar
• Jenkins S, Yang JC, Ramalingam SS, et al. Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non-Small Cell Lung Cancer. J Thorac Oncol. 2017;12(7):1061–1070.
   PubMed Web of Science ®Google Scholar
• Guardant Health Guardant360 CDx First FDA-Approved Liquid Biopsy for Comprehensive Tumor Mutation Profiling Across All Solid Cancers [Internet]. Redwood City (CA): Guardant Health; [cited 2021 Jan 18]. Available from: https://investors.guardanthealth.com/press-releases/press-releases/2020/Guardant-Health-Guardant360-CDx-First-FDA-Approved-Liquid-Biopsy-for-Comprehensive-Tumor-Mutation-Profiling-Across-All-Solid-Cancers/default.aspx
   Google Scholar
• FDA Approves Foundation Medicine’s FoundationOne Liquid CDx, a Comprehensive Pan-Tumor Liquid Biopsy Test with Multiple Companion Diagnostic Indications for Patients with Advanced Cancer [Internet]. Cambridge (MA): Foundation Medicine; [cited 2021 Jan 18]. Available from: https://www.foundationmedicine.com/press-releases/445c1f9e-6cbb-488b-84ad-5f133612b721
   Google Scholar
• Yarchoan M, Hopkins A, Jaffee EM. Tumor Mutational Burden and Response Rate to PD-1 Inhibition. N Engl J Med. 2017;377(25):2500–2501.
   PubMed Web of Science ®Google Scholar
• Marabelle A, Fakih M, Lopez J, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020;21(10):1353–1365.
   PubMed Web of Science ®Google Scholar
• Gandara DR, Paul SM, Kowanetz M, et al. Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab. Nat Med. 2018;24(9):1441–1448.
   PubMed Web of Science ®Google Scholar
• Cescon DW, Bratman SV, Chan SM, et al. Circulating tumor DNA and liquid biopsy in oncology. Nat Cancer. 2020;1(3):276–290.
   PubMedGoogle Scholar
• Ståhlberg A, Krzyzanowski PM, Egyud M, et al. Simple multiplexed PCR-based barcoding of DNA for ultrasensitive mutation detection by next-generation sequencing. Nat Protoc. 2017;12(4):664–682.
   PubMed Web of Science ®Google Scholar
• Ståhlberg A, Krzyzanowski PM, Jackson JB, et al. Simple, multiplexed, PCR-based barcoding of DNA enables sensitive mutation detection in liquid biopsies using sequencing. Nucleic Acids Res . 2016;44(11):e105.
   PubMed Web of Science ®Google Scholar
• Tan L, Sandhu S, Lee RJ, et al. Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA. Ann Oncol. 2019;30(5):804–814.
   PubMed Web of Science ®Google Scholar
• Sausen M, Phallen J, Adleff V, et al. Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients. Nat Commun. 2015;6:7686.
   PubMed Web of Science ®Google Scholar
• Olsson E, Winter C, George A, et al. Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease. EMBO Mol Med. 2015;7(8):1034–1047.
   PubMed Web of Science ®Google Scholar